Anzeige
Mehr »
Login
Samstag, 20.07.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Wenn die FDA dies genehmigt, könnte das Wunder für diese kleine Aktie bedeuten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DSES | ISIN: CA88105E1088 | Ticker-Symbol: TED
Tradegate
18.07.24
17:18 Uhr
1,220 Euro
+0,040
+3,39 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TERRASCEND CORP Chart 1 Jahr
5-Tage-Chart
TERRASCEND CORP 5-Tage-Chart
RealtimeGeldBriefZeit
1,1501,17013:04
1,1601,19019.07.
GlobeNewswire (Europe)
120 Leser
Artikel bewerten:
(0)

TerrAscend Announces Results of Annual General Meeting

TORONTO, June 17, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced the results of its annual meeting of shareholders held on June 17, 2024 (the "Meeting"). Common shareholders at the Meeting affirmatively approved the following resolutions:

  • the election of Mr. Craig Collard, Ms. Ira Duarte, Mr. Ed Schutter, Ms. Kara DioGuardi and Mr. Jason Wild as directors of the Company;
  • the ratification of the appointment of MNP LLP as the independent public accounting firm of the Company for the fiscal year ended December 31, 2024; and
  • the approval of a resolution to amend the expiry dates of stock options held by certain employees and directors of the Company, as further described in the Company's Management Information Circular and Proxy Statement.

The Toronto Stock Exchange ("TSX") has neither approved nor disapproved the contents of this news release. Neither the TSX nor any securities regulator accepts responsibility for the adequacy or accuracy of this release.

About TerrAscend

TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including vertically integrated operations in Pennsylvania, New Jersey, Maryland, Michigan and California through TerrAscend Growth Corp. and retail operations in Canada through TerrAscend Canada Inc. ("TerrAscend"). TerrAscend operates The Apothecarium, Gage and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend's cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend's operations and financial performance.

For more information regarding?TerrAscend:
Keith Stauffer
Chief Financial Officer
717-343-5386
IR@terrascend.com

Briana Chester
MATTIO Communications
424-465-4419
terrascend@mattio.com


© 2024 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.